GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation
Alcami Builds cGMP Biostorage Facility in North Carolina
65,000-square-foot facility to provide a broad range of cGMP pharmaceutical and biologics storage...
Alcami Completes Next Phase of Biopharma Storage Expansion at Masy BioServices
The completion of Phase II expansion doubles the capacity of ambient pallet storage at 15°C to 30°C
GHO Capital and The Vistria Group to acquire Alcami
GHO Capital and The Vistria Group to acquire Alcami, a leading high growth CDMO, from Madison...
Press Release: Alcami Adds Solid-State Characterization Capabilities
Morrisville, North Carolina – September 22, 2022 – Alcami, a U.S.-based pharmaceutical contract...
Alcami Partners with Civica Rx in Multi-Year Agreement
Wilmington, N.C. – May 3, 2022 – Alcami, a leading United States-based contract development and...
Alcami Expands Biopharma Storage at Masy BioServices
New Facility Adds 160,000 ft² of cGMP Pallet Storage Space
Parenteral Market Trends
With today’s growing pipeline of biologics, namely complex oncology products often delivered...
Alcami Adds Additional Formulation Development Capabilities
Formulation Development Suite to Support Small and Large Molecule Programs
Morrisville, North...
Alcami Attending DCAT Week 2022
As a proud member of the Drug, Chemical & Associated Technologies Association, Alcami is pleased to...
Alcami Expands Biologics Footprint with Investment in Durham
$10 Million Investment Doubles Laboratory Footprint & Enhances Large Molecule and Cell & Gene...
Bioanalytical Testing Trends in 2022
An increasing number of clinical trial registrations, more R&D investment, growing demand for...
EMPQ Case Study: Carolina Components Group
Read this case study to learn how Alcami supported Carolina Components Group in the successful...
Alcami Announces the Acquisition of Masy BioServices
Acquisition to add 375,000 ft² of cGMP Biostorage and Pharma Support Services
Alcami to Provide Analytical Support Services for Novavax’ COVID-19 Vaccine Candidate
DURHAM, N.C. – November 16, 2021 – Alcami, a leading United States-based contract development and...
Outsourcing Trends in the Development of Biologics
The development of biologic drugs continues to increase at a rapid pace. Growing numbers of...
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3...
Alcami Announces Parenteral Operations Leadership Appointments
DURHAM, N.C. – October 12, 2021 - Alcami, a leading United States-based contract development and...
Alcami Expands Parenteral Operations with Additional Investment
CHARLESTON, S.C. – September 29, 2021 - Alcami, a leading United States-based contract development...
Alcami Appoints Timothy Compton as Chief Business Officer
25-year industry professional brings a track record of leading high-performing, client-centered...
Fill-Finish Development Challenges & Solutions for CDMOs
Recently, contract development and manufacturing organizations (CDMOs) involved in the...
Case Study: OSD Formulation Development
Client Profile
The client needed formulation development of an oral dosage form from scratch. They...
White Paper: Host Cell Impurities, Bioassays, Micro-Flow Imaging
As opposed to traditional drug production, the production of biological products (biologics)...
QbD Addresses API Supply in Orphan Drug Formulation
According to the Food and Drug Administration and the Orphan Drug Designation program, orphan...
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
The agreement represents another step toward the proprietary manufacturing, formulation, and...
EDITORIAL: Combination Products and their Regulatory Pathway
Combination products are becoming increasingly important to pharmaceutical CDMOs like Alcami, said...
On-Demand Lab Open House
From standalone projects through full-service programs, our laboratories provide solutions to your...
Wilmington Business Journal Spotlight: Pharmaceutical Pipeline
Alcami is proud to call Wilmington, North Carolina their headquarters. In this spotlight, Alcami...
Alcami Appoints Patrick D. Walsh as Chairman & Chief Executive Officer
Wilmington, N.C. – March 18, 2021 – Alcami, a global pharmaceutical contract development and...
On Demand Webinar: Microbial In-Use Studies
Microbial in-use (admixture) studies are performed to evaluate the growth of low-level...
On Demand Webinar: Combination Products & The CDMO
You're invited to take part in a now on demand webinar. During this webinar, regulatory and quality...
Outsourcing Analytical Testing- Innovative Drugs Spike Demand for Advanced Analysis
The global pharmaceutical analytical testing outsourcing market was estimated at $6.1 billion in...
Alcami Adds Gerteis and Low Humidity Suites to Wilmington, NC
Alcami, a leading United States-based contract development and manufacturing organization...
Alcami Voices: Risk Mitigation in the CDMO Space
Although there is no such thing as a truly “crisis-proof” organization, how are you working to...
White Paper: Leveraging Inductively Coupled Plasma Mass Spectrometry To Its Full Potential
Today’s technology has not only changed the way we receive information, but has continually adapted...
Editorial: Prepping Fill/Finish Systems to Ensure Quality Output
A holistic approach to validation and quality assurance is essential.
Biologic drugs are highly...
On Demand Webinar: Beyond Elemental Impurities - New Applications of ICP-MS
You're invited to attend our on demand virtual event. During this webinar, scientific experts will ...
Alcami Continues to Execute Strategic Plan to Focus Its Platform with Sterling Pharma Solutions’ Acquisition
Global contract development and manufacturing organisation (CDMO), Sterling Pharma...
Virtual Open House: New Sterile Fill-Finish Development & Manufacturing Facility
We're kicking off the opening of our new formulation and sterile fill-finish facility with a...
Blog: Food Interaction Studies 101
Alcami’s scientists have substantial experience designing and executing food interaction studies...
Alcami RTP Expansion Nears Completion
MORRISVILLE, N.C., July 28, 2020 -- Alcami, a US-based contract development and manufacturing...
Blog: 505(b)(2): What You Need to Know
In recent years 505(b)(2) approvals have experienced double-digit growth. Many companies are...
Editorial: Reducing Risk with Abuse-Deterrent Formulations
Increasing prevalence of drug misuse and abuse is driving a heightened and more stringent approach...
Alcami Bolsters Leadership Team with Quality & Regulatory Appointments
WILMINGTON, NC – May 21, 2020 – Alcami, a North Carolina-based contract development and...
Alcami Appoints EVP of Drug Product Operations and VP of Laboratory Operations
WILMINGTON, NC – MAY 18, 2020 – Alcami, a North Carolina-based contract development and...
Component Selection Equates to Successful Sterile Fill-Finish Manufacturing
As a contract manufacturer, Alcami provides experience in all aspects of the manufacturing process,...
Blog: Successful Methods for Obtaining Orphan Drug Approval
Signed into law on January 4, 1983, the Orphan Drug Act (ODA) allows for granting special status to...
Alcami Supporting Potential COVID-19 Treatment
WOODCLIFF LAKE, N.J. —April 16, 2020— Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”), a New...
Challenge Accepted! Problem-Solving Examples for Packaging Dilemmas
Even well-designed product formulations can fail if it is contained in inappropriate packaging. How...